Business Context and Reporting Period
This Form 8-K was filed by Pieris Pharmaceuticals, Inc. on April 18, 2016. The report details a material definitive agreement entered into on the same date between Pieris Pharmaceuticals, Inc. and its wholly-owned subsidiary, Pieris Pharmaceuticals GmbH, with Enumeral Biomedical Holdings, Inc. (Enumeral).
Key Financial Metrics and Agreement Terms
The filing outlines a license and transfer agreement for the development of fusion proteins (PD-1 antibodies linked to Anticalin proteins) for oncology. Key financial terms include:
- Upfront License Fee: $250,000 payable upon execution.
- Maintenance Fee: $750,000 payable on May 31, 2016.
- Development Milestones: Up to an aggregate of $37.8 million for all products and indications.
- Sales Milestones: Up to an aggregate of $67.5 million for all products and indications.
- Royalties: Low to lower-middle single digits percentage of net sales, subject to reduction by up to 50% if third-party license fees are incurred.
- Option Exercise: An undisclosed upfront payment is required if Pieris exercises an option to license an additional antibody within twelve months.
The filing text does not provide current revenue, profit, cash flow, margins, debt, or liquidity figures for the company.
Material Changes
The primary material change is the acquisition of a non-exclusive worldwide license (exclusive in the field of licensed antibodies fused to Anticalin proteins in oncology) to Enumeral's patent rights and know-how. This agreement establishes new contingent liabilities and future cash outflow obligations for Pieris.
Outlook, Risks, and Contingencies
Management Commentary and Outlook: The agreement enables Pieris to research, develop, and market specific fusion proteins in the oncology area. Pieris holds an option for twelve months to license an additional antibody from Enumeral.
Risks and Contingencies:
- Termination: Pieris may terminate the agreement on 30 days' notice. Enumeral may terminate on 60 days' notice for material breach (or 30 days for payment breach) if uncured.
- Automatic Termination: The agreement automatically terminates if Pieris fails to make the $750,000 maintenance fee payment.
- Third-Party Obligations: Royalty payments to Enumeral may be reduced if Pieris must pay license fees to third parties.
Investor Verification Checklist
- Verify the cash impact of the $250,000 upfront fee and the upcoming $750,000 maintenance fee due May 31, 2016.
- Review the full text of the License and Transfer Agreement (to be filed as an exhibit to the Form 10-Q for the quarter ended March 31, 2016) for detailed milestone definitions.
- Assess the potential cash flow impact of the undisclosed upfront payment if the option to license an additional antibody is exercised.
- Monitor the company's ability to meet the maintenance fee deadline to avoid automatic termination of the license.